18 research outputs found
Knowledge/Attitude/Practices of HPV & Cervical Cancer, Willingness to Participate in Vaccine Trial in Preparation for HIV & HPV Vaccine Trials in Mali
Oral Presentation from AIDS Vaccine 2012 Boston, MA, USA. 9-12 September 201
Sicherung der Strukturqualität in der stationären medizinischen Rehabilitation von Kindern und Jugendlichen
The gap between desires and reality in sexuality of males and females aged 60 and over: Results from the Berlin aging study II (BASE-II)
Entry of Panton–Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus into the hospital: prevalence and population structure in Heidelberg, Germany 2015–2018
Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center
Purpose!#!Diagnosis and treatment of breast cancer have changed profoundly over the past 25Â years. The outcome improved dramatically and was well quantified for early stage breast cancer (EBC). However, progress in the treatment of metastatic disease has been less convincingly demonstrated. We have studied survival data of patients with metastatic breast cancer (MBC) from a large academic cancer center over a period of 20Â years.!##!Methods!#!Data from 1033 consecutive MBC patients who were treated at the Department of Medical Oncology of the West German Cancer Center from January 1990 to December 2009 were retrospectively analyzed for overall survival (OS) and risk factors. Patients were grouped in 5-year cohorts, and survival parameters of each cohort were compared before and after adjustment for risk factors.!##!Results!#!Overall survival of patients with MBC treated at specialized center has significantly improved from 1990 to 2010 (hazard ratio 0.7, 95%CI 0.58-0.84). The increments in OS have become less profound over time (median OS 1990-1994: 24.2Â months, 1995-1999: 29.6Â months, 2000-2004: 36.5Â months, 2005-2009: 37.8Â months).!##!Conclusion!#!Survival of patients with MBC has improved between 1990 and 2004, but less from 2005 to 2009. Either this suggests an unnoticed shift in the patient population, or a lesser impact of therapeutic innovations introduced in the most recent period